Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression

Drugs of Today

Volumn 35, Issue 9, 1999, Pages 719-724

  Baldwin, David S ^a,b   Carabal, Eloisa ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; MUSCARINIC RECEPTOR; REBOXETINE;

DEPRESSION; DOPAMINE UPTAKE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; REVIEW;

EID: 0032758222     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.9.553217     Document Type: Review

References (11)

1. Anderson, I.M., Tomenson, B.M. Treatment discontinuation with selective serotonin re-uptake inhibitors compared with tricyclic antidepressants: A meta-analysis. Br Med J 1994, 310: 1433-8.
2. Montgomery, S.A. Reboxetine: Additional benefits to the depressed patient. J Psychopharmacol 1997, 11 (4, Suppl.): S9-15.
3. Baldwin, D.S., Hawley, C.J., Szabadi, E. et al. Reboxetine in the treatment of depression: Early clinical experience in the UK. Int J Psychiatry Clin Pract 1998, 2: 195-201.
4. Dostert, P., Benedetti, M.S., Poggesi, I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997, 7 (Suppl. 1): S23-35.
5. Strolin Benedetti, M., Frigerio, E., Tochetti, P. et al. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 1995, 7: 285-9.
6. Riva, M., Brunello, N., Rovescalli, A.C. et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies. J Drug Dev 1989, 1 (4): 243-53.
7. Cocchiara, G., Battaglia, R., Pevarello, P., Strolin Benedetti, M. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 1991, 16: 231-9.
8. Rey, E., Dostert, P., D'Athis, P., Jannuzo, M.G., Poggesi, I., Olive, G. Dose proportionality of reboxetine enantiomers in healthy male volunteers. 6th World Conf Clin Pharmacol Ther (Aug 4-9, Buenos Aires) 1996, Abst.
9. Edwards, D.M.F., Pellizoni, C., Breuel, H.P. et al. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995, 16: 443-60.
10. Theofilopoulos, N., McDade, G., Szabadi, E., Bradshaw, C.M. Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex. Br J Clin Pharmacol 1995, 39: 251-5.
11. Kerr, J.S., Powell, J., Hindmarch, I. The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Br J Clin Pharmacol 1996, 42: 239-41.